Abstract
Sertoli-Leydig cell tumors (SLCTs) are rare tumors. Mass and pain are the presenting feature. The varying histopathology and differentiation of this tumor present difficulties with proper diagnosis and development of optimal treatment regimens. The prognosis depends on tumors grading and staging. Surgery is main stay management option. Chemotherapy and radiation options are still of choice. We aimed to present Sertoli-Leydig cell tumor managed surgical at Latifa Hospital in Dubai, UAE with acceptable outcome and good patient satisfaction.
Highlights
Sertoli-Leydig cell tumors (SLCTs) are rare tumors, accounting for less than 0.5% of all ovarian cancers
We aimed to present Sertoli-Leydig cell tumor managed surgical at Latifa Hospital in Dubai, UAE with acceptable outcome and good patient satisfaction
Prognosis of ovarian SLCTs is significantly correlated with degree of tumor grading and staging
Summary
Sertoli-Leydig cell tumors (SLCTs) are rare tumors, accounting for less than 0.5% of all ovarian cancers. The varying histopathology and differentiation of this tumor present difficulties with proper diagnosis and development of optimal treatment regimens [1]. Very few case reports have been documented in the literature so far [2]. Prognosis of ovarian SLCTs is significantly correlated with degree of tumor grading and staging. Management of ovarian SLCTs remains challenging owing to lack of standardized management protocol guidelines [3]. The role of postoperative chemotherapy remains questionable and is only indicated in patients with poor prognostic factors [2]. We report the case of a Sertoli-Leydig cell tumor found in a 19-year-old female with intermediate differentiation and heterologous elements (mainly epithelial components: gastrointestinal, hepatocellular and respiratory), with intact.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have